These companies could innovate their way to success.

The polycystic kidney disease drugs market offers opportunities through therapeutic innovation, patient-centric care models, ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

A 9,000 percent rise since 2015 in overdose deaths involving fentanyl among adults over 65 is prompting a statewide effort to provide older adults with the information they need to age safely. An ...

CFOs, including Gunnar Wiedenfels of Warner Bros Discovery and Colette Kress of Nvidia, addressed disciplined spending, ...

The International Society for Stem Cell Research (ISSCR) today opened its sold-out international symposium, Accelerating ...

On November 18, 2025, ToolGen, Inc. (“ToolGen”) filed a complaint (“Complaint”) in the District of Massachusetts alleging infringement of its ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 195 % for ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...